LifeProNow
FEBRUARY 2, 2025
January 30, 2025: “The U.S. The most common adverse reactions in study participants who received Journavx were itching, muscle spasms, increased blood level of creatine phosphokinase, and rash. Journavx is contraindicated for concomitant use with strong CYP3A inhibitors.
Express Pharma
JUNE 3, 2024
The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. by the 2024/2025 respiratory virus season,” the statement informs. No serious safety concerns were identified in the Phase 3 trial. The post Moderna receives U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Business Review
SEPTEMBER 2, 2024
The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. The CDC’s Advisory Committee on Immunization Practices unanimously recommended the use of the 2024-2025 COVID-19 vaccines for individuals as young as six months in June this year.
Express Pharma
JANUARY 15, 2025
The FDA has set a Prescription Drug User Fee Act (PDUFA) action date for August 31, 2025. Additionally, the FDA accepted Eisais Supplemental Biologics License Application (sBLA) for monthly LEQEMBI IV maintenance dosing in June 2024, with a PDUFA action date set for January 25, 2025. Eisai holds final decision-making authority.
The Thyroid Pharmacist
MARCH 7, 2025
An adverse reaction to mold can be a trigger for Hashimotos, asthma, and other autoimmune conditions. [23] Accessed February 20, 2025. Published online January 6, 2025. Accessed February 20, 2025. Accessed February 27, 2025. Some molds produce toxic secondary metabolites called mycotoxins. 3] Faber S.
Expert insights. Personalized for you.
130 
Let's personalize your content